Form 4: Atara Bio Officer Sells Shares for Tax Obligations

Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold shares to cover tax withholding obligations related to vested restricted stock units.

Summary

• Chief Accounting Officer Yanina Grant-Huerta sold shares of Atara Biotherapeutics, Inc. common stock.
• The transactions occurred on August 18, 2025.
• A total of 1,809 shares were sold across three separate transactions.
• The shares were sold at prices of $11.609, $11.613, and $11.614 per share, resulting in an approximate weighted average sale price of $11.61 per share.
• These sales were non-discretionary, executed automatically to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units, as per a sale-to-cover provision.
• Following these reported transactions, Yanina Grant-Huerta beneficially owns 35,258 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a neutral event for the company's stock price and does not indicate a change in management's outlook.

Positives

• The vesting of restricted stock units indicates the fulfillment of equity compensation for the Chief Accounting Officer.

Risks

• Potential misinterpretation of the sale as a discretionary insider divestment rather than a mandatory tax-related transaction.

Future Outlook

NA

Management Comments

• Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
• The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Industry Context

This transaction is a routine insider filing for tax purposes, common across all industries for employees receiving equity compensation. It does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary divestment indicating a change in management's confidence.
• Employees: Indicates the vesting of equity compensation for the Chief Accounting Officer, which is a standard component of executive compensation packages.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by a corporate officer to satisfy tax withholding obligations upon the vesting of restricted stock units. This type of transaction is common and does not typically indicate a change in management's view of the company's prospects, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, Corporate Officer, Beneficial Ownership